Cspc Innovation Pharmaceutical Co.,Ltd.(300765),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

300765 Cspc Innovation Pharmaceutical Co.,Ltd.

Closed 09-18 15:00:00

43.88

+0.61

+1.41%

High44.80	Low43.10	Vol16.79M
Open43.38	D1 Closing43.27	Amplitude3.93%
Mkt Cap61.65B	Tradable Cap61.65B	Total Shares1.41B
T/O737.00M	T/O Rate1.19%	Tradable Shares1.41B
P/B15.44	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"300765","market":"SZ","secType":"STK","nameCN":"Cspc Innovation Pharmaceutical Co.,Ltd.","latestPrice":43.88,"timestamp":1789714998000,"preClose":43.27,"halted":0,"volume":16789416,"delay":0,"changeRate":0.0141,"floatShares":1405000000,"shares":1405000000,"eps":0.7282,"marketStatus":"Closed","change":0.61,"latestTime":"09-18 15:00:00","open":43.38,"high":44.8,"low":43.1,"amount":737000000,"amplitude":0.0393,"askPrice":43.89,"askSize":13,"bidPrice":43.88,"bidSize":226,"shortable":0,"etf":0,"ttmEps":0.7282,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789954200000},"marketStatusCode":5,"adr":0,"adjPreClose":43.27,"symbolType":"stock","openAndCloseTimeList":[[1789695000000,1789702200000],[1789707600000,1789714800000]],"highLimit":47.6,"lowLimit":38.94,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1404592944,"isCdr":false,"pbRate":15.44,"roa":"--","peRate":60.258171,"roe":"38.2%","epsLYR":-0.1731,"committee":0.296524,"marketValue":61634000000,"turnoverRate":0.012,"status":0,"floatMarketCap":61634000000},"requestUrl":"/m/hq/s/300765/wiki","defaultTab":"wiki","newsList":[{"id":"2667018674","title":"CSPC Innovation Pharmaceutical Gets Breakthrough Therapy Designation for Lung Cancer Investigational Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2667018674","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667018674?lang=en_us&edition=fundamental","pubTime":"2026-09-16 12:33","pubTimestamp":1789533191,"startTime":"0","endTime":"0","summary":"CSPC Innovation Pharmaceutical  subsidiary Megalith Pharmaceutical received breakthrough therapy designation from China's National Medical Products Administration for its SYS6010 investigational drug.The drug is indicated for patients with driver gene-negative non-squamous non-small cell lung cancer after failing immunotherapy and platinum-based chemotherapy, according to a Tuesday after-hours filing with the Shenzhen bourse.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667166376","title":"CSPC Innovation Pharmaceutical's SYS6010 Shows Promise in Lung Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2667166376","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667166376?lang=en_us&edition=fundamental","pubTime":"2026-09-15 13:18","pubTimestamp":1789449508,"startTime":"0","endTime":"0","summary":"CSPC Innovation Pharmaceutical  subsidiary Jushi Biopharmaceutical presented Phase I/II data for SYS6010 at the 2026 World Conference on Lung Cancer in Seoul.Among 123 patients, confirmed objective response rates reached 58.9% and 49.2% for the two dosing regimens, according to a Monday aftermarket filing with the Shenzhen bourse.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664389515","title":"CSPC Innovation Pharma's SYS6010 Lands China's Breakthrough Therapy Product List","url":"https://stock-news.laohu8.com/highlight/detail?id=2664389515","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664389515?lang=en_us&edition=fundamental","pubTime":"2026-09-02 12:31","pubTimestamp":1788323495,"startTime":"0","endTime":"0","summary":"CSPC Innovation Pharmaceutical's  drug, SYS6010, was included in the Breakthrough Therapy Product List of China's National Medical Products Administration, according to a Shenzhen bourse filing on Tuesday.The Chinese pharmaceutical company's shares rose 2% during Wednesday's morning trade.The drug, which was developed by subsidiary Shijiazhuang CSPC Jushi Biopharmaceutical, is used for the treatment of patients with relapsed or metastatic head and neck squamous cell carcinoma who have failed to respond to immunotherapy and platinum-containing chemotherapy.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196860177","title":"Cspc Innovation's Subsidiary Drug SYS6010 Granted Breakthrough Therapy Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=1196860177","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196860177?lang=en_us&edition=fundamental","pubTime":"2026-09-01 17:18","pubTimestamp":1788254311,"startTime":"0","endTime":"0","summary":"Cspc Innovation Pharmaceutical Co.,Ltd. (300765.SZ) has announced that its majority-owned subsidiary, CSPC Group MegaStone Biopharmaceutical Co., Ltd., has received Breakthrough Therapy Designation...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664387168","title":"CSPC Innovation Pharmaceutical's Subsidiary Starts Phase I Trial of SYH2092 Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2664387168","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664387168?lang=en_us&edition=fundamental","pubTime":"2026-09-01 13:12","pubTimestamp":1788239562,"startTime":"0","endTime":"0","summary":"CSPC Innovation Pharmaceutical's  subsidiary, CSPC Jushi Biopharmaceutical, started the phase I clinical trial of SYH2092 injection, according to a Shenzhen bourse filing late Monday.The drug is being developed for weight management in patients with obesity and to help improve glycemic control of adult patients with type 2 diabetes mellitus.The drug is undergoing testing to evaluate its safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of SYH2092 in healthy participants.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662051982","title":"CSPC Innovation Pharmaceutical Subsidiary Gets China Clinical Trial Nod for Weight Loss Injection; Shares Fall 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662051982","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662051982?lang=en_us&edition=fundamental","pubTime":"2026-08-28 14:20","pubTimestamp":1787898022,"startTime":"0","endTime":"0","summary":"CSPC Innovation Pharmaceutical  subsidiary CSPC Jushi Biopharmaceutical received clinical trial approval from China's National Medical Products Administration for its SYH2092 injection, according to a Thursday after-hours filing with the Shenzhen bourse.The drug is an amylin receptor agonist and is indicated for weight loss.Shares in the drug company fell 5% during afternoon trading on Friday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662483775","title":"CSPC Innovation Pharma's Colorectal Cancer Drug Gets US FDA's Fast Track Designation; Shares Up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662483775","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662483775?lang=en_us&edition=fundamental","pubTime":"2026-08-27 14:51","pubTimestamp":1787813504,"startTime":"0","endTime":"0","summary":"CSPC Innovation Pharmaceutical's  first-in-class PD-1/IL-15 bispecific fusion protein, SYS6090 , received a fast track designation from the U.S. Food and Drug Administration, according to a Wednesday disclosure on the Shenzhen bourse.The Chinese pharmaceutical company's shares rose 4% during Thursday's afternoon trade.The drug is developed by the company's subsidiary, CSPC Giant Biopharmaceutical, as a treatment for patients with microsatellite-stable or mismatch repair-proficient metastatic colorectal cancer.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","300765","BK0226","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662147775","title":"CSPC Innovation Pharmaceutical's Phase 3 Trial for Lung Cancer Drug Achieves Primary Endpoint of Progression-Free Survival","url":"https://stock-news.laohu8.com/highlight/detail?id=2662147775","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662147775?lang=en_us&edition=fundamental","pubTime":"2026-08-27 14:49","pubTimestamp":1787813363,"startTime":"0","endTime":"0","summary":"CSPC Innovation Pharmaceutical  subsidiary CSPC Jushi Biopharmaceutical's phase 3 trial for its SYS6010 lung cancer drug reached its primary endpoint of progression-free survival, according to a Thursday disclosure to the Shenzhen Stock Exchange.The drug exhibited better progression-free survival than current treatments, with statistically and clinically significant differences, as well as good safety, the filing said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660409093","title":"CSPC Innovation Pharma's Subsidiary Starts Trial for SYS6090 Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2660409093","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660409093?lang=en_us&edition=fundamental","pubTime":"2026-08-20 15:16","pubTimestamp":1787210199,"startTime":"0","endTime":"0","summary":"CSPC Innovation Pharmaceutical's  subsidiary, CSPC Jushi Biopharmaceutical, initiated the phase Ib/II clinical trial of SYS6090 injection as a treatment for hepatocellular carcinoma, according to a Shenzhen bourse filing on Wednesday.The Chinese pharmaceutical company's shares slipped during Thursday's afternoon trade.The open-label, multicenter clinical trial looks into the safety and efficiency of the drug as a combination therapy.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169059614","title":"CSPC Innovation Subsidiary Initiates Phase Ib/II Clinical Trial for SYS6090","url":"https://stock-news.laohu8.com/highlight/detail?id=1169059614","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169059614?lang=en_us&edition=fundamental","pubTime":"2026-08-19 16:04","pubTimestamp":1787126666,"startTime":"0","endTime":"0","summary":"Cspc Innovation Pharmaceutical Co., Ltd. (300765.SZ) has announced that its controlling subsidiary, CSPC Megalith Biopharmaceutical Co., Ltd., recently kicked off a Phase Ib/II clinical trial...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBQ","MDTX","300765","BK0226","IBBJ","PSYK","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660487988","title":"CSPC Innovation Posts RMB 1.26 Billion H1 Net Profit on RMB 3.24 Billion Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2660487988","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660487988?lang=en_us&edition=fundamental","pubTime":"2026-08-17 20:19","pubTimestamp":1786969143,"startTime":"0","endTime":"0","summary":"CSPC Innovation posts RMB 1.26 billion H1 net profit on RMB 3.24 billion revenueCSPC’s subsidiary CSPC Innovation reported 1H 2026 revenue of RMB 3.24 billion, up 208.72% year on year.Net profit attri","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDL28Hkdn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0661504455.SGD","LU2114397693.USD","LU2237443895.HKD","LU2324357040.USD","LU2091194634.USD","LU1267930813.SGD","IE00B5MMRT66.SGD","LU1226288170.HKD","LU1226288253.USD","BK1515","LU0882574055.USD","LU0047473722.SGD","LU0390134368.USD","LU0315179316.USD","LU1023059063.AUD","LU1960683339.HKD","LU0052756011.USD","LU1807302812.USD","LU1267930490.SGD","LU1003077747.HKD","LU0128525689.USD","LU0140636845.USD","LU0211326839.USD","LU1863844665.USD","LU0203347892.USD","LU1046234339.USD","KURE","300765","LU3187612489.SGD","LU1196032939.SGD","BK1521","LU0266013472.USD","LU0784385840.USD","LU1261432733.SGD","LU0738911758.USD","LU2112291526.USD","LU1951186391.HKD","01093","AZN.UK","LU2237443622.USD","LU1983299246.USD","LU1104425308.USD","03165","HK0000165453.HKD","LU0964806797.USD","LU0784383803.USD","IE00B543WZ88.USD","LU0920840948.USD","SGXZ57979304.SGD","LU1061106388.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156632772","title":"Cspc Innovation Pharmaceutical Reports Net Profit of 1.261 Billion Yuan in First Half After Turning Losses Around","url":"https://stock-news.laohu8.com/highlight/detail?id=1156632772","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156632772?lang=en_us&edition=fundamental","pubTime":"2026-08-17 16:51","pubTimestamp":1786956680,"startTime":"0","endTime":"0","summary":"Cspc Innovation Pharmaceutical Co., Ltd. (300765.SZ) has released its semi-annual report for the first half of 2026, showing a significant turnaround. The company achieved operating revenue of 3.24...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660553485","title":"CSPC Innovation Pharmaceutical H1 Net Profit 1.3 Billion Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=2660553485","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660553485?lang=en_us&edition=fundamental","pubTime":"2026-08-17 16:49","pubTimestamp":1786956561,"startTime":"0","endTime":"0","summary":"Aug 17 (Reuters) - CSPC Innovation Pharmaceutical Co., Ltd. <300765.SZ>::*H1 NET PROFIT 1.3 BILLION YUAN ($192.94 million)((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))Source Date/Time = 17-AUG-202608:33:31 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nRSD7jdYvX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B5MMRT66.SGD","LU1152091168.USD","LU1226288253.USD","LU0315179316.USD","LU1008478684.HKD","SG9999004220.SGD","LU1951186391.HKD","LU1993786604.SGD","LU1152091754.HKD","BK0226","IE00BZ08YS42.EUR","IE00B543WZ88.USD","LU1960683339.HKD","LU0314109678.HKD","LU0326950275.SGD","IE00BZ08YR35.GBP","BK1191","BK1521","IE0008369823.USD","HK0000165453.HKD","LU1813983027.USD","LU0072913022.USD","IE00B031HY20.USD","IE00BZ08YT58.USD","LU2039709279.SGD","LU1226287792.SGD","BK1515","LU1328277881.USD","LU0140636845.USD","LU0067412154.USD","LU1226287529.USD","LU1226288170.HKD","LU1807302812.USD","LU1226287875.USD","01093","300765","IE0008368742.USD","KURE","LU0880133367.SGD","LU0501845795.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660483136","title":"CSPC Innovation Pharmaceutical H1 Net Profit 1.3 Bln Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=2660483136","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660483136?lang=en_us&edition=fundamental","pubTime":"2026-08-17 16:33","pubTimestamp":1786955611,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nL4N44E0GL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659618035","title":"CSPC Innovation Pharmaceutical Gets $30 Million Initial Payment for Nucleic Acid Development Deal With AstraZeneca","url":"https://stock-news.laohu8.com/highlight/detail?id=2659618035","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659618035?lang=en_us&edition=fundamental","pubTime":"2026-08-13 11:43","pubTimestamp":1786592598,"startTime":"0","endTime":"0","summary":"CSPC Innovation Pharmaceutical , through unit Jushi Biosciences, received the initial payment of $30 million from AstraZeneca for the development of the small nucleic acid pipeline, according to a Wednesday disclosure on the Shenzhen bourse.The Chinese pharmaceutical company's shares rose 2% during Thursday's morning trade.Jushi Biosciences signed a deal with AstraZeneca in July to develop nucleic acids for drug production.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101412793","title":"Cspc Innovation's Subsidiary Receives $30 Million Upfront Payment from AstraZeneca","url":"https://stock-news.laohu8.com/highlight/detail?id=1101412793","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101412793?lang=en_us&edition=fundamental","pubTime":"2026-08-12 18:56","pubTimestamp":1786532201,"startTime":"0","endTime":"0","summary":"Cspc Innovation Pharmaceutical Co., Ltd. (300765.SZ) announced that on July 1, 2026, its controlling subsidiary, Jushi Biologics, signed a Collaboration, Option, and License Agreement with...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0029864427.USD","AZNH","LU0128525929.USD","BK4588","LU2468319806.SGD","LU2089984988.USD","IE00B3T34201.USD","LU2237443382.USD","LU0109394709.USD","BK4585","LU2456880835.USD","LU2236285917.USD","LU2237443895.HKD","LU0289739699.SGD","AZN","LU2237443978.SGD","300765","BK4007","LU2237443622.USD","LU0058720904.USD","LU0432979614.USD","LU0889565916.HKD","LU1829250122.USD","LU1267930573.SGD","LU0310800379.SGD","LU2462157665.USD","LU0708994859.HKD","LU0320765992.SGD","BK0226","LU2237443549.SGD","BK4568","LU2237443465.HKD","LU2417539215.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658964487","title":"CSPC Innovation Pharmaceutical Unit Receives FDA Clearance for Monkeypox Vaccine Trial; Shares Up 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658964487","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658964487?lang=en_us&edition=fundamental","pubTime":"2026-08-11 13:42","pubTimestamp":1786426962,"startTime":"0","endTime":"0","summary":"CSPC Innovation Pharmaceutical  subsidiary CSPC Jushi Biopharmaceutical received U.S. Food and Drug Administration clearance to conduct clinical trials of its SYS6037 monkeypox vaccine candidate.The investigational new drug application for the vaccine passed safety review by the U.S. FDA, according to an after-hours filing on Monday with the Shenzhen bourse.Shares jumped nearly 6% during afternoon trading on Tuesday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LABU","BK0226","300765","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186200098","title":"Cspc Innovation Subsidiary Gets FDA Clearance for Monkeypox mRNA Vaccine Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1186200098","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186200098?lang=en_us&edition=fundamental","pubTime":"2026-08-10 15:52","pubTimestamp":1786348339,"startTime":"0","endTime":"0","summary":"Cspc Innovation Pharmaceutical Co.,Ltd. (300765.SZ) announced that its controlling subsidiary, CSPC Megalith Biopharmaceutical Co., Ltd., received notification from the U.S. Food and Drug...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDTX","MRNX","IBBJ","300765","MRNY","BMED","PSYK","BK0226","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656584815","title":"CSPC Innovation Pharmaceutical Launches Phase Ib/II Trial for Colorectal Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2656584815","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656584815?lang=en_us&edition=fundamental","pubTime":"2026-08-04 12:31","pubTimestamp":1785817914,"startTime":"0","endTime":"0","summary":"CSPC Innovation Pharmaceutical  subsidiary MegaStone started a Phase Ib/II clinical trial for SYS6090 injection in patients with advanced or metastatic colorectal cancer.The open-label, multi-center trial will evaluate the safety, tolerability and efficacy of the combination regimen, according to a Monday aftermarket filing on the Shenzhen bourse.Patient recruitment is underway.Shares of the company rose 2% in recent trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196848313","title":"Cspc Innovation Pharmaceutical Initiates Phase Ib/II Trial for SYS6090 Combination Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1196848313","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196848313?lang=en_us&edition=fundamental","pubTime":"2026-08-03 16:38","pubTimestamp":1785746310,"startTime":"0","endTime":"0","summary":"The company Cspc Innovation Pharmaceutical Co.,Ltd. (300765.SZ) has announced that its controlled subsidiary, CSPC Megalith Biopharmaceutical Co., Ltd., has recently launched a Phase Ib/II clinical...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSYK","300765","BMED","IBBQ","IBBJ","MDTX","BK0226"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1789919024391,"stockEarnings":[{"period":"1week","weight":0.0349},{"period":"1month","weight":0.0169},{"period":"3month","weight":0.8322},{"period":"6month","weight":0.4549},{"period":"1year","weight":-0.1529},{"period":"ytd","weight":0.2165}],"compareEarnings":[{"period":"1week","weight":0.0061},{"period":"1month","weight":0.0045},{"period":"3month","weight":-0.0437},{"period":"6month","weight":-0.0114},{"period":"1year","weight":0.0209},{"period":"ytd","weight":-0.0144}],"compareStock":{"symbol":"000001.SH","name":"SSE Comp"},"companyName":"石药创新制药股份有限公司","boardCode":"AI0014","boardName":"食品制造业","stockholders":"33821人(较上一季度增加7.25%)","perCapita":"41530股","listingDate":"2019-03-22","address":"河北省石家庄市栾城区张举路62号","registeredCapital":"140459万元","survey":"　　石药创新制药股份有限公司的主营业务是生物制药、功能性原料及保健食品的研发、生产与商业化。公司的主要产品是抗体药物、ADC药物、mRNA疫苗、药品、咖啡因、阿卡波糖、无水葡萄糖原料及果维康维生素C含片、维生素B族含片。公司是国内首批实现mRNA疫苗产业化、ADC与抗体药物管线布局最完整的创新型生物药企业之一，已发展成为集源头创新、临床转化、规模生产与国际商业化于一体的高新技术企业。","listedPrice":24.47},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cspc Innovation Pharmaceutical Co.,Ltd.(300765),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Cspc Innovation Pharmaceutical Co.,Ltd.(300765) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Cspc Innovation Pharmaceutical Co.,Ltd.,300765,Cspc Innovation Pharmaceutical Co.,Ltd.股票,Cspc Innovation Pharmaceutical Co.,Ltd.股票老虎,Cspc Innovation Pharmaceutical Co.,Ltd.股票老虎国际,Cspc Innovation Pharmaceutical Co.,Ltd.行情,Cspc Innovation Pharmaceutical Co.,Ltd.股票行情,Cspc Innovation Pharmaceutical Co.,Ltd.股价,Cspc Innovation Pharmaceutical Co.,Ltd.股市,Cspc Innovation Pharmaceutical Co.,Ltd.股票价格,Cspc Innovation Pharmaceutical Co.,Ltd.股票交易,Cspc Innovation Pharmaceutical Co.,Ltd.股票购买,Cspc Innovation Pharmaceutical Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cspc Innovation Pharmaceutical Co.,Ltd.(300765),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Cspc Innovation Pharmaceutical Co.,Ltd.(300765) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction